Novo Nordisk Says Semaglutide Cleared Obesity In 40% Of Children Tested

Novo Nordisk, the maker of Wegovy, announced that its drug semaglutide cleared obesity in 40% of children tested in a clinical trial. The results highlight potential expanded use of the blockbuster weight-loss drug in pediatric populations. The company is expected to seek regulatory approval for treating childhood obesity. The findings could reshape treatment approaches for young patients globally.